Toxicidad pulmonar asociada a inmunoterapia con Nivolumab : presentación de un caso.

Toxicidad pulmonar asociada a inmunoterapia con Nivolumab : presentación de un caso.

Contenido principal del artículo

Ingrid Juliana Moreno Ladino
Ana Milena Callejas Gutiérrez
Edgar Alberto Sánchez Morales
Alfredo Saavedra Rodríguez

Resumen

Toxicidad pulmonar asociada a inmunoterapia con Nivolumab

Detalles del artículo

Referencias (VER)

Nishino M, Ramaiya NH, Awad MM, Sholl LM4, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF HF. PD-1 inhibitor-related pneumonitis in advanced cancer. Clin Cancer Res [Internet]. 2016;22(24):6051–60. Available from : https://www.ncbi.nlm.nih.gov/pubmed/27535979

Nishino M, Giobb ie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitorrelated pneumonitis in patients with advanced cancer a systematic review and meta-analysis. JAMA Oncol . 2016;2(12):1607–16.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapyin Patients with Advanced Cancer:AMeta-Analysis.Oncologist.2017;22(4):470–9.

Khunger M, Rakshit S, Pasupuleti V, Hernandez AV., Mazzone P, Stevenson J,et al. Incidence of programmed cel l death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis . Oncologist [Internet].2017;157631(4):709–17.Available from:http://dx.doi.org/10.1016/j.chest.2017.04.177

Naidoo J, Wang X, Woo K M, Iyriboz T, HalpennyD, Cunningham J,et al. Pneumonitis in patients treated with antiprogrammed death-1/programmed death ligand 1 therapy. JClin Oncol.2017;35(7):709–17.

Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.The Lancet RespiratoryMedicine.2018.

Citado por